{
    "Overall_score": {
        "Correlation": 8,
        "Sentiment": 7,
        "Importance": 8,
        "Impact": 7,
        "Duration": 6,
        "Virality": 5,
        "Source_Score": 7,
        "Specificity": 8,
        "Sector_Spread": 9,
        "Tech_Mentions": 3
    },
    "Each_item": [
        {
            "News_content": "AMGN in ABC Bullish Pattern, Targets",
            "Correlation": 7,
            "Sentiment": 8,
            "Importance": 6,
            "Impact": 6,
            "Duration": 4,
            "Virality": 3,
            "Source_Score": 6,
            "Specificity": 5,
            "Sector_Spread": 5,
            "Tech_Mentions": 8
        },
        {
            "News_content": "Today's pharma news covering NVS, GSK, AMGN, Kyprolis, JNJ, Takeda, Velcade, Gilead Sciences, Natco Pharma",
            "Correlation": 6,
            "Sentiment": 5,
            "Importance": 5,
            "Impact": 4,
            "Duration": 3,
            "Virality": 7,
            "Source_Score": 7,
            "Specificity": 4,
            "Sector_Spread": 10,
            "Tech_Mentions": 2
        },
        {
            "News_content": "AMGN - Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis (carfilzomib) Over Velcade",
            "Correlation": 9,
            "Sentiment": 8,
            "Importance": 9,
            "Impact": 8,
            "Duration": 7,
            "Virality": 6,
            "Source_Score": 8,
            "Specificity": 9,
            "Sector_Spread": 8,
            "Tech_Mentions": 3
        },
        {
            "News_content": "AMGN says its study found Kyprolis had double PFS vs Velcade in relapsed multiplemyeloma patients: 18.7 months vs 9",
            "Correlation": 10,
            "Sentiment": 9,
            "Importance": 10,
            "Impact": 9,
            "Duration": 8,
            "Virality": 5,
            "Source_Score": 9,
            "Specificity": 10,
            "Sector_Spread": 7,
            "Tech_Mentions": 2
        }
    ]
}